Edith Conlon, a 58-year-old mother of three, has been diagnosed with breast cancer three times, with the latest recurrence being more aggressive. While chemotherapy can manage her cancer, there's a risk of resistance, and the novel drug Enhertu offers a viable alternative. However, Enhertu is not available on the NHS in England and Wales due to pricing negotiations with AstraZeneca and Daiichi Sankyo, leaving thousands of women without access to this potentially life-saving treatment. Maria Conlon, Edith's daughter, has launched an online fundraiser to pay for private treatment, highlighting the stark contrast between the availability of Enhertu in Scotland and other European countries and its unavailability in England and Wales. Maria's efforts are not just about raising funds but also about raising awareness of the need for Enhertu and the injustice of its pricing on the NHS.
Maria, a 22-year-old trainee teacher, has been a pillar of support for her mother, sharing her experiences and the emotional rollercoaster they've endured. She emphasizes the importance of Enhertu in offering better survival rates and treatment options, especially for her mother's type of cancer. The family's resilience and positive attitude, despite the challenging circumstances, are remarkable. Edith's strength and humor, even in the face of adversity, have inspired her family and the community.
The fundraising campaign, which aims to cover the approximately £8,000 monthly cost of private treatment, has already received overwhelming support. Maria's determination to raise awareness and her personal commitment to the Race for Life are testaments to her dedication. She believes that her efforts can make a difference, not only for her mother but also for other women who might need Enhertu in the future. The family's story underscores the importance of accessibility to life-saving treatments and the need for continued advocacy in healthcare.
The article concludes by encouraging readers to support Edith's treatment through Maria's GoFundMe page, emphasizing the broader impact of this personal struggle on the broader healthcare system. It also highlights the importance of raising awareness and advocating for better access to essential treatments, leaving a lasting impact on the community and potentially influencing policy changes.
